Cramer's lightning round: Onto Innovation is 'going to go lower'

CNBC
Original Story by CNBC
November 19, 2026
Cramer's lightning round: Onto Innovation is 'going to go lower'

A recap of Jim Cramer’s Mad Money lightning-round-style discussion features varied stock takes from a panel. Onto Innovation is forecast to decline, framed as overpriced in a Fed-tightened environment, while other names receive mixed-to-optimistic or cautious theses, such as UiPath being inexpensive but lacking catalysts and Affirm advocating a staged entry. The conversations reflect a risk-tolerant stance toward some names and a bearish tilt on others, with room for tactical buys and patience depending on price levels and macro signals. The segment underscores prevailing market tension between inflation-fighting policy and stock-specific catalysts, hinting at continued volatility and selective accumulation. Viewers are left with a sense that positioning will hinge on macro moves and price reinforcements in the near term.

Dive Deeper:

  • Onto Innovation is characterized as a good company but deemed likely to go lower due to its high valuation in the current environment where the Fed is fighting inflation.

  • UiPath is described as a cheap stock but lacking catalysts, leading to a conclusion that it should be avoided or voted off the island in the near term.

  • Karman Holdings expresses strong conviction, signaling a belief that the stock is mispriced and worth backing despite broader market headwinds.

  • Affirm outlines a staged buy strategy, suggesting initial purchases at around $56, then incremental buys at $50 and $45, tied to confidence in CEO Max Levchin's numbers.

  • Nio is labeled a high-risk, low-price bet with the possibility of significant downside, with one panelist noting a zero-auspice scenario for $2 stocks.

  • Alnylam Pharmaceuticals is viewed as inexpensive, yet some participants favor Regeneron, Vertex, and Amgen as comparatively stronger choices.

  • The discussion blends price targets, risk tolerance, and macro considerations, signaling that stock picks will depend on price levels and evolving Fed policy.

Latest News

Related Stories